BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 2410098)

  • 1. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
    Verhoef V; Fridland A
    Cancer Res; 1985 Aug; 45(8):3646-50. PubMed ID: 2410098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and selectivity of arabinonucleoside in human lymphoid cells.
    Fridland A; Verhoef V
    Proc Soc Exp Biol Med; 1985 Sep; 179(4):456-62. PubMed ID: 2991939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts.
    Shewach DS; Daddona PE; Ashcraft E; Mitchell BS
    Cancer Res; 1985 Mar; 45(3):1008-14. PubMed ID: 3971358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells.
    Shewach DS; Mitchell BS
    Cancer Res; 1989 Dec; 49(23):6498-502. PubMed ID: 2819707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase.
    Rodriguez CO; Mitchell BS; Ayres M; Eriksson S; Gandhi V
    Cancer Res; 2002 Jun; 62(11):3100-5. PubMed ID: 12036920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
    Gandhi V; Plunkett W
    Cancer Res; 1988 Jan; 48(2):329-34. PubMed ID: 3335008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of arabinosyl nucleotides in K562 human leukemia cells.
    Gandhi V; Plunkett W
    Biochem Pharmacol; 1989 Oct; 38(20):3551-8. PubMed ID: 2479383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
    Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T
    Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in human leukemia cells by deoxycytidine 5'-triphosphate.
    Liliemark JO; Plunkett W
    Cancer Res; 1986 Mar; 46(3):1079-83. PubMed ID: 3484676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step.
    Rodriguez CO; Gandhi V
    Cancer Res; 1999 Oct; 59(19):4937-43. PubMed ID: 10519407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells.
    Rodriguez CO; Legha JK; Estey E; Keating MJ; Gandhi V
    Clin Cancer Res; 1997 Nov; 3(11):2107-13. PubMed ID: 9815603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity.
    Tanaka M; Yoshida S
    Jpn J Cancer Res; 1987 Aug; 78(8):851-7. PubMed ID: 3115933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies.
    Lambe CU; Averett DR; Paff MT; Reardon JE; Wilson JG; Krenitsky TA
    Cancer Res; 1995 Aug; 55(15):3352-6. PubMed ID: 7614470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate.
    Catapano CV; Chandler KB; Fernandes DJ
    Cancer Res; 1991 Apr; 51(7):1829-35. PubMed ID: 1706219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
    Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
    Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
    Abe I; Saito S; Hori K; Suzuki M; Sato H
    Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF; Huang P; Plunkett W; Gandhi V
    Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells.
    Xie C; Plunkett W
    Cancer Res; 1995 Jul; 55(13):2847-52. PubMed ID: 7540950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2'-Fluoro-2',3'-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2',3'-dideoxyadenosine.
    Masood R; Ahluwalia GS; Cooney DA; Fridland A; Marquez VE; Driscoll JS; Hao Z; Mitsuya H; Perno CF; Broder S
    Mol Pharmacol; 1990 Apr; 37(4):590-6. PubMed ID: 2109183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.